Mapracorat, a novel selective glucocorticoid receptor agonist, inhibits hyperosmolar-induced cytokine release and MAPK pathways in human corneal epithelial cells

PURPOSE: Increasing evidence suggests that tear hyperosmolarity is a central mechanism causing ocular surface inflammation and damage in dry eye disease. Mapracorat (BOL-303242-X) is a novel glucocorticoid receptor agonist currently under clinical evaluation for use in the treatment of dry eye disea...

Descripción completa

Detalles Bibliográficos
Autores principales: Cavet, Megan E., Harrington, Karen L., Ward, Keith W., Zhang, Jin-Zhong
Formato: Texto
Lenguaje:English
Publicado: Molecular Vision 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2932489/
https://www.ncbi.nlm.nih.gov/pubmed/20824100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2932489/
https://www.ncbi.nlm.nih.gov/pubmed/20824100

Ejemplares similares